Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939102 | 0.86 | GPR55 (0.37) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL21566579 | 0.84 | MAPT (0.44) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL13508872 | 0.77 | KCNQ3 (0.40) | MAPTTP53THRB | |
| SCHEMBL4616475 | 0.77 | MAPT (0.51) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL745588 | 0.75 | SIGMAR1 (0.48) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL8281885 | 0.75 | SIGMAR1 (0.45) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL3035789 | 0.75 | BRPF1 (0.47) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL4615636 | 0.75 | HTR1A (0.45) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| SCHEMBL4614580 | 0.75 | SIGMAR1 (0.53) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 | |
| Hydrochloric Acid SCHEMBL7818310 | 0.74 | BRPF1 (0.46) | SIGMAR1MAPTHTR1AHTR2CCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200289502-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2016-04-21 | — | — | US | disclosed |
| US-9193701-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-24 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140194402-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | SIGMAR1 3121/4885MAPT 3114/4885HTR1A 4647/4885 |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | PCK1, PDK3, PDK2 | SIGMAR1 3121/4885MAPT 3114/4885HTR1A 4647/4885 |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | SIGMAR1 3121/4885MAPT 3114/4885HTR1A 4647/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | SIGMAR1 3936/4885MAPT 2867/4885HTR1A 4695/4885 |
| US-20200289502-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | SIGMAR1 3121/4885MAPT 3114/4885HTR1A 4647/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | SIGMAR1 4303/4885MAPT 4344/4885HTR1A 4561/4885 |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | SIGMAR1 3936/4885MAPT 2867/4885HTR1A 4695/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | SIGMAR1 3936/4885MAPT 2867/4885HTR1A 4695/4885 |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | SIGMAR1 3936/4885MAPT 2867/4885HTR1A 4695/4885 |
| US-20140194402-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | SIGMAR1 3121/4885MAPT 3114/4885HTR1A 4647/4885 |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | SIGMAR1 3433/4885MAPT 3834/4885HTR1A 4514/4885 |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | SIGMAR1 1830/4885MAPT 3609/4885HTR1A 3784/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | SIGMAR1 1910/4885MAPT 3592/4885HTR1A 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.